李锋

2017-06-19

李锋,博士,北京天广实生物技术股份有限公司总经理,入选第六批国家千人计划。回国前历任美国Genentech公司首席工程师、中试车间经理;Amgen公司资深科学家;Tanox公司工艺工程师。具有全面技术和管理经验。拥有美国专利2项,发表学术论文20余篇。2011年9月回国以来,引进了由美国Genentech公司产业化经验的4名科学家组成的核心技术团队,建立了国际水平的抗体研发技术平台。公司在研抗体产品10余个,已获得临床批件4项,承担国家及省部级科研项目13项。主持开发的抗埃博拉抗体药物MIL77 在100天内完成快速构建和应急生产,2015年在英国和意大利成功治愈了濒危感染患者,创造了抗体应急生产的中国速度并首创国产抗体药物救治西方发达国家患者。

Dr. Feng Li is currently CEO of Beijing Mab-Works, Inc., a biotech company focusing on therapeutic antibody development. Before joining Mab-Works in late 2011, Feng has worked in US bioPharm industry for over 10 years. He was a Principle Engineer, Manager of Pilot Plant and Cell Culture Development at Genentech, Inc., a Senior Scientist at Amgen, Inc., and a Process Engineer at Tanox, Inc. Feng received his Ph.D. degree in Chemical Engineering from Rice University.


上一篇:张志民
下一篇:叶常青
Powered by 飞色网络